When a family receives a rare genetic diagnosis, the variant is often the clearest thing in front of them. The gene is named. The mutation is characterized. The molecular consequence — a destroyed splice site, a toxic gain-of-function, a pseudoexon inserted into the transcript — is documented. Antisense oligonucleotide therapy is frequently a sound candidate: over a dozen ASO drugs are FDA-approved, the mechanism is in principle applicable to nearly any transcribed gene, and the field is expanding faster than any other modality in rare disease.
But until now, every route to getting an ASO designed ran through an institution. None were built for the person who actually needs the drug.
How the gap was created
Academic design tools are free and scientifically serious. They also require bioinformatics expertise to run, produce raw thermodynamic scores with no synthesis pathway, and output nothing that can be handed to a physician or a manufacturer. The workflow from raw output to a usable candidate takes weeks and assumes knowledge patients do not have and should not need.
Contract design and synthesis organizations were built for pharmaceutical companies with drug programmes. Costs begin in the tens of thousands of dollars. Their processes — institutional procurement, NDAs, multi-month timelines — are not structured for a single patient or a single physician.
Nonprofit programmes have criteria that most families do not meet. The admission threshold — typically fewer than 30 patients worldwide sharing the same mutation — was designed for nano-rare diseases. Families with uncommon but not astronomically rare mutations do not qualify, and for those who do, development takes years.
The practical result: a family with a well-characterized pathogenic variant, a disease biology compatible with ASO therapy, and a physician prepared to pursue it has had no way to commission a design directly. Every route required either institutional infrastructure or a mutation so rare that it qualified for a programme designed for exceptional cases.
What Pequliar is
Pequliar is the design layer — not a pharma company, not a drug developer, but the AI engine that produces the asset pharma companies spend years and millions to build internally.
A physician or family submits a medical file. The platform reasons across all eight documented ASO mechanisms, identifies the applicable strategy for the specific variant, generates candidates, scores them against thermodynamic and empirical criteria derived from the published ASO literature and from structural analysis of every FDA-approved ASO drug, screens them for off-target binding across the human transcriptome, and returns a ranked design with chemistry assigned. A complete amenability assessment — whether the variant is likely to respond to ASO therapy, and by what mechanism — is free. A full design report is $399.
A second service tier carries the output through synthesis, release testing, and first dose. This is the path that did not exist before: the complete route from a genetic diagnosis to a first administered dose, commissioned directly by a physician or family, without requiring a drug development programme, a research collaboration, or a nonprofit application.
In blind validation — FDA-approved ASO drugs withheld from training and re-presented as unknown targets — the platform recovered the exact sequence and chemistry of seven of fifteen approved drugs within its top-ten candidates. The best academic tool recovered three.
What the output is and is not
The candidates Pequliar produces are computationally derived. They carry predicted thermodynamic and selectivity properties, not experimentally confirmed ones. Experimental validation — testing candidates in patient-derived cells, confirming target engagement, evaluating safety — is required before any therapeutic use, and Pequliar's output does not substitute for that step.
What the platform provides is the starting point that has never before been directly accessible: a structured, expert-level design specific to a patient's variant, in a form that can be discussed with a physician, handed to a synthesis provider, and used to initiate whatever development path the family and their medical team decide to pursue.
The design layer has always existed. For the first time, a patient can commission it.